Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of the Stop Imatinib (STIM1) study with a long follow-up.
INTRODUCTION
The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) dramatically improved outcome for patients with chronic myeloid leukemia in chronic phase (CML-CP), now considered a model disease for targeted therapy. [1] [2] [3] With TKI therapy, most of the patients with CML-CP achieve deep molecular responses, as measured by quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR). [4] [5] [6] [7] In addition to data suggesting that patients with deep molecular responses have a low risk of progression and a high rate of long-term survival, 8, 9 several ongoing discontinuation clinical trials have demonstrated that patients with sustained deep molecular responses can safely suspend TKI therapy and achieve treatment-free remission. [10] [11] [12] [13] [14] [15] [16] [17] Indeed, we have already reported the preliminary results of the imatinib (IM) discontinuation study called "STIM1" for "stop imatinib." Interim analysis showed that nearly 40% of the patients maintained a molecular remission after IM cessation despite persistent leukemic cells at a low level in most if not all patients. 10, 18, 19 Moreover, no case of progression was reported after IM discontinuation, and treatment rechallenge in patients with molecular recurrence (MR) was associated with the occurrence of a second deep molecular response, suggesting that IM discontinuation in selected patients is safe.
Similar results have been reported in a comparable cohort of patients with a short follow-up. 12 Although the definition of MR leading to treatment resumption was slightly different, the common feature was that most cases of MR occur during the first months after IM cessation. To date, the most important issue concerns the occurrence of late MR with a long-term follow-up after cessation of TKIs.
Here we report the updated results of the STIM1 study based on the analysis of the whole study patient population (N = 100) with a median follow-up of 77 months after IM discontinuation.
PATIENTS AND METHODS

Patients
Patients who were age 18 years or older with Philadelphia chromosome-positive CML-CP at diagnosis who were treated with ongoing IM at any dose for at least 3 years and in sustained undetectable molecular residual disease (UMRD) for at least 2 years, were eligible for inclusion at one of the 19 participating French centers. Patients who had previous allogeneic stem-cell transplantation, who were undergoing treatment of concomitant other malignancy, or who had been treated with immunomodulatory agents other than interferon alfa (IFN-a) were excluded. Previous treatments that included autologous stem-cell transplantation or IFN-a alone or in combination with cytarabine or IM were allowed. Written informed consent was obtained for all patients. The ethics committee, in agreement with the French public health code, approved the protocol.
Study Evaluations
Sustained UMRD required at least six undetectable BCR-ABL transcripts assessed by quantitative RT-PCR performed as previously reported. 10 Molecular follow-up was performed once per month in the first year after IM cessation, once every 2 months in the second year, and once every 3 months thereafter. After 2 years of follow-up, the molecular monitoring was performed by local laboratories according to European LeukemiaNet recommendations and was expressed on the International Scale (IS). 20 MR was defined as at least two positive RT-PCR results showing a significant increase (by 10 times; ie, one log), at two consecutive assessments or loss of major molecular response (MMR).
Statistical Methods
Time to MR was measured from the date of IM discontinuation to the date of MR or the date of last molecular examination for patients who did not relapse. We estimated molecular recurrence-free survival (MRFS) by using the Kaplan-Meier method.
We tested the potential prognostic value of age at diagnosis, sex, Sokal and Eutos risk score, previous IFN-a, duration of IM, time to UMRD, and duration of UMRD until discontinuation of IM for MR. These parameters were tested by univariable and multivariable analyses, first over time and then at 6 months because most events occurred up to the 6-month threshold. After checking assumptions for each of these variables, exploratory analyses over time were performed by using Fine and Gray and regression models and accounting for competing events. The strength of the association between each predictor variable and the outcome was assessed by using the subdistribution hazard ratio, which is the ratio of hazards associated with the cumulative incidence function. A backward stepwise procedure was used. In these models, quantitative variables were categorized according to their median value. Logistic regression analyses were performed at 6 months. Quantitative variables were not dichotomized in these models.
Potential prognostic factors were considered for multivariable analyses at an a level less than .20. The covariates were then considered as additive of prognostic information to each other at an a level of .05. Corresponding 95% CIs were obtained for every significant estimate. All comparative analyses were two-sided. Analyses were performed by using SAS v 9.3 (SAS Institute, Cary, NC) and R (The R Foundation for Statistical Computing) software.
RESULTS
From July 2007 to December 2009, 117 patients were enrolled in the STIM1 study. Seventeen of them were BCR-ABL1 positive at the BCR-ABL:ABL centralized assessment and were excluded from the study. In all, 100 patients were included of whom 50 were previously treated with IFN-a. Patient characteristics are listed in Table 1 . At the time of the analysis, the median molecular follow-up after IM discontinuation was 77 months (range, 9 to 95 months) overall and 80 months (range, 55 to 93 months) for the 38 patients alive without MR. Sixty-one patients (61%) had confirmed MR, and one patient died with UMRD at 10 months. The MRFS was 43% (95% CI, 33% to 52%) at 6 months, 40% (95% CI, 30% to 49%) at 18 months, and 38% (95% CI, 29% to 47%) at 60 months (Fig 1) .
MR
MR occurred mostly within 6 months after IM discontinuation. Forty-nine (80% of relapsing patients) MRs occurred from month 1 to month 3, nine (15%) from month 4 to month 7, and three (5%) from month 18 to month 22. No MRs were reported thereafter. The cumulative incidence of MR, accounting for competing events (one patient died with UMRD), is presented in Figure 2 .
The median time to MR was 2.5 months (range, 0.9 to 22.3 months), and the median BCR-ABL:ABL IS ratios at the time of first and second consecutive assessments were 0.008% (range, 0.0004% to 0.201%) and 0.032% (range, 0.011% to 1.54%), respectively. Seventeen patients had MMR loss at the date of the confirmed MR with a median BCR-ABL:ABL IS of 0.28% (range, 0.14% to 1.54%). Four patients had MR later than 6 months after IM discontinuation at 7, 18, 20, and 22 months, respectively. The Sokal risk score was low (n = 2) or intermediate (n = 2), and three patients had received prior IFN-a therapy with a time duration of 4, 16, and 53 months, respectively, for IFN.
Therapy was restarted in 57 of 61 MR patients (IM in 56 patients, dasatinib in one patient) with a median duration between MR and treatment resumption of 2.1 months (range, 0.7 to 15.6 months). Four patients did not restart treatment at the time of MR, three for refusal to resume therapy and one because of chemotherapy for concomitant second neoplasm.
Fifty-five of the 57 patients who restarted treatment achieved a second UMRD with a median time to UMRD of 4.3 months (range, 1.5 to 21 months). MR patients with or without loss of MMR at the date of relapse had a median time to second UMRD after treatment resumption of 4.2 months (range, 1.5 to 15.8 months) and 5 months (range, 2.3 to 21 months), respectively.
With a median molecular follow-up of 73 months, none of the MR patients had CML progression. Four patients died as a result of causes unrelated to CML. Two patients died as a result of second malignancies (pleural mesothelioma, metastatic gastric adenocarcinoma) and two as a result of other causes (one case each of acute renal failure and cerebral hemorrhage). At the last available molecular assessment before death, all patients were at least in MMR (UMRD, n = 2; MMR, n = 2). Fifty-seven patients were alive at the last follow-up. Forty-three patients (70%) were receiving TKI therapy and 14 were free of TKIs. Among the latter, nine patients who had achieved a sustained UMRD after TKI resumption underwent a second (n = 8) or a third (n = 1) TKI discontinuation without MMR loss. Two patients who restarted treatment did not achieve a second UMRD because of treatment interruptions related to recurrent grade 2 adverse events. Three patients who refused to restart therapy maintained at least an MMR. Patients' disposition, treatment, and molecular status at the last date of the follow-up are summarized in Table 2 . 21 
Non-MR
With a median molecular follow-up of 79.9 months (range, 8.9 to 93.3 months), 39 patients (39%) remained free from MR as defined in the study and free from TKI therapy at the time of last assessment. Among them, one patient died as a result of acute myocardial infarction 9 months after IM discontinuation. At the last available molecular evaluation, 37 of the 39 patients were in UMRD and two patients had a positive BCR-ABL:ABL IS ratio (MR4; ie, 4-log reduction of BCR-ABL1 transcript).
Since IM discontinuation, 16 (41%) of the 39 non-MR patients had sustained UMRD whereas 23 patients (59%) had intermittent positive BCR-ABL:ABL IS ratio assessment with median highest BCR-AB:ABL IS ratio of 0.0017% (range, 0.0008% to 0.0162%). None of the intermittently positive patients had experienced MMR loss or MR according to the study definition.
Predictive Factors for MR
Age, sex, Sokal and Eutos risk scores, previous IFN-a therapy, duration of IM therapy, time to UMRD, and UMRD duration until IM discontinuation were analyzed as potential predictive factors for MR over time by using univariable analysis (Table 3) . After multivariable analyses, only Sokal risk score (low plus intermediate v high, P = .024) and IM duration (duration less than median v more than median, P = .024) remained independent significant prognostic factors (Table 3 and Fig 3A) . IM duration was then analyzed at different cutoffs to identify the time on treatment that was associated with the most significant probability of being free from MR. When adjusted to the Sokal risk score, IM duration longer than 54 months was associated with a lower risk of MR ( Fig  3B) . Combination of the two factors showed that patients with low or intermediate Sokal risk score and IM duration longer than 54 months had a significantly lower incidence of MR when compared with the other patients (Fig 3C) . Most of the MR occurred during the first 6 months after IM discontinuation. The baseline variables were then analyzed according to the probability of MR by 6 months (n = 57). By multivariable analysis, Sokal risk group was the only variable associated with a significant probability of MR (P = .0149 overall; P = .0184 for low-v intermediate-risk; P = .0273 for low-v high-risk Sokal groups) at 6 months.
DISCUSSION
With a median follow-up of 77 months for the whole study population (n = 100), MRFS was 43% at 24 months and 38% at 60 months in this analysis of the STIM1 study. Although the definition of MR was slightly different, rate of MR after IM discontinuation in patients with CML who were selected by using the same criteria as that in the TWISTER (Australian Leukaemia and Lymphoma Group CML8) study was very similar: 45% of the 40 patients were free from MR with a median follow-up of 43 months. 12 At this time, several other IM discontinuation studies have estimated the incidence of MR as being from 19% to 67%.
11, [13] [14] [15] [16] [17] This wide discrepancy can be partially explained by the heterogeneity of the baseline characteristics of the patients, the follow-up since IM discontinuation, and last but not least by the definition of MR. Indeed, definition of MR has changed over Abbreviations: AE, adverse event; MMR, major molecular response; MR, molecular response; MR 4.5 , molecular response 4.5-log; TKI, tyrosine kinase inhibitor. *Twenty-one patients who had achieved a second sustained undetectable molecular residual disease (UMRD) of at least 1 year had a second treatment discontinuation as previously described. 21 Of those patients, 13 had MR leading to treatment resumption, and eight were free from MR with a median follow-up of 11.6 months (range, 0.9 to 21.4 months) after second imatinib discontinuation and without TKIs at last follow-up. Among the 13 MR patients, four achieved a third sustained UMRD and one experienced a third treatment discontinuation without molecular recurrence at the last date of follow-up.
†One patient died as a result of pleural mesothelioma while receiving imatinib. The remaining three patients discontinued TKI therapy because of worsening concomitant disease leading to death (one patient case each of cerebral hemorrhage, metastatic gastric adenocarcinoma, and acute renal failure).
ascopubs.org/journal/jco time. Because IM cessation was an exploratory tool, the first discontinuation studies were very cautious, and MR leading to treatment resumption was defined as a confirmed positive detection of BCR-ABL1 transcript irrespective of the molecular level of the transcript. [10] [11] [12] [13] [14] [15] 17 However, some patients who had MR according to this definition did not resume treatment, mainly for patient convenience, and they experienced a spontaneous decrease or a sustained detectable BCR-ABL1 transcript at a very low level without significant molecular progression over time. 22 On the basis of these observations, the loss of MMR has been proposed and evaluated as a trigger for treatment resumption in the A-STIM (According to Stop Imatinib) study. 22 Thus, the loss of MMR was considered a valuable criterion for defining MR and is currently proposed as the main criteria to define MR in different TKI discontinuation studies. 16, 23 In this study, four patients experienced MR after 6 months, but no other MRs had been reported after 2 years with a median follow-up of more than 6 years. With a shorter follow-up, similar results were observed in the TWISTER study. 12 Despite changes in the definition of MR, all these studies agree that MR occurs mainly in the 3 to 6 months after IM discontinuation, although some infrequent MRs have been reported later.
The safety of IM discontinuation remains a key issue. Five patients died during follow-up as a result of causes unrelated to CML, and no progression event was reported in this study. Currently, all patients with MRs have achieved a second deep molecular response after treatment resumption provided that patients were rechallenged with TKIs. With the exception of one patient reported in the A-STIM study who regained MMR 4 months after IM resumption and experienced lymphoid blast crisis 4 months after that, no CML progression event was reported in IM discontinuation studies, [11] [12] [13] [14] [15] [16] [17] 22 which supports the safety of TKI discontinuation in selected patients. Of note, TKI withdrawal syndrome, a musculoskeletal pain syndrome first described by Richter et al, 24 was not reported in this study, probably because of a shorter IM exposure before stopping compared with that in other studies. 24, 25 We hypothesize that a careful selection of patients on the basis of a sustained deep molecular response before IM may partially explain the success of IM discontinuation. Whether patients who do not achieve such sustained deep molecular response are not good candidates for IM discontinuation remains debatable. Optimal depth and duration of molecular response before TKI discontinuation are currently under investigation in the panEuropean EURO-SKI (European Stop Tyrosine Kinase Inhibitor Study) study. 26 Close molecular monitoring together with a prompt TKI resumption after MR is also important in the setting of TKI discontinuation. Aside from the fact that stopping TKIs remains a critical option from the patient's point of view, 27 patient's adherence to TKI resumption after MR should be carefully monitored. Whether patients can discontinue TKIs outside the context of a clinical trial is a critical question. 28 We must keep in mind that experiences of IM discontinuation are currently based on a prospective discontinuation with a retrospective selection of patients. We might accept stopping TKIs if molecular follow-up is performed according to international recommendations by using selection criteria recently proposed by Hughes and Ross 29 but only for IM. The second objective of this update analysis was to identify MR predictive factors based on the analysis of the whole study population (N = 100) and with a longer follow-up after IM discontinuation. Again, highest Sokal risk score and IM duration exposure were significantly associated with the risk of MR over time. We next evaluated the IM exposure duration associated with the most significant probability of remaining free from MR. When adjusted to Sokal risk score, IM duration of at least 54 months was associated with a lower risk of MR. Only Sokal risk score was identified as being significantly associated with MR by 6 months. Sokal risk score and IM duration have also been correlated with MR in several other discontinuation studies.
14,15,17 However, in this study, Sokal risk score continues to be a strong significant factor associated with early and late MR, suggesting that eradication of the leukemic clone may depend on intrinsic baseline features of the disease. Taking into account the occurrence of late MR, duration of IM exposure was also associated with the probability of MR, suggesting that a longer drug exposure may also contribute to the erosion of the leukemic stem cell clone, especially in patients with a low Sokal risk score. To date, several discontinuation studies pointed out that a prior treatment with IFN-a and/or duration of IFN-a therapy may be associated with a lower risk of MR. 12, 14, 22 In this study, we were unable to demonstrate that prior IFN-a treatment had a significant impact on the risk of MR. Preliminary results of the ongoing French STIM2 (Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib) study-a discontinuation study restricted to IM de novo patients who achieved a sustained UMRD-demonstrate a rate and calendar of MR similar to that in the STIM1 study. 29a We must keep in mind that the patient population of the STIM1 study is heterogeneous, with half the patients previously exposed to IFN-a. Together with the size of the cohort, these characteristics may limit the statistical analysis of such predictive factors.
Whether improvement of results will be observed in patients treated with second-generation TKIs as first-or second-line therapy is currently being evaluated in ongoing discontinuation trials. 23, 30, 31 Indeed, discontinuation of dasatinib as second-line therapy in the DADI (Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukaemia Who Have Maintained Deep Molecular Response for Longer Than 1 Year) trial was associated with a probability of treatment-free remission of 49% at 6 months and 48% at 12 months. 31 Several randomized clinical studies have demonstrated that second-generation TKIs as first-or second-line therapies are associated with higher rates and faster deep molecular responses when compared with IM.
32- 34 We can now hypothesize that the proportion of patients who will achieve a sustained deep molecular response and will be eligible for treatment discontinuation according to the STIM1 criteria will increase over time. Whether a shorter exposure to second-generation TKIs together with the achievement of a sustained deep molecular response will be associated with similar rates of MR remains a key issue.
In conclusion, the long follow-up of the STIM1 study confirms that IM discontinuation is safe. With respect to the heterogeneous characteristics of the patients, Sokal risk score and IM duration before treatment discontinuation have to be considered from the perspective of IM discontinuation. These results make treatment-free remission legitimate as a criterion of treatment evaluation in the future.
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